Cargando…

Talking to patients with heart failure about end of life

Detalles Bibliográficos
Autores principales:	Campbell, Ross T., Petrie, Mark C., McMurray, John J.V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2018
Materias:	Research Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607510/ https://www.ncbi.nlm.nih.gov/pubmed/30295978 http://dx.doi.org/10.1002/ejhf.1321

Ejemplares similares

Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it
por: Ahmad, Faheem A., et al.
Publicado: (2019)

Association is not causation: treatment effects cannot be estimated from observational data in heart failure
por: Rush, Christopher J, et al.
Publicado: (2018)

Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction
por: Packer, Milton, et al.
Publicado: (2021)

Palliative care needs in patients hospitalized with heart failure (PCHF) study: rationale and design
por: Campbell, Ross T., et al.
Publicado: (2015)

Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: a systematic review and meta-analysis
por: Curtain, James P, et al.
Publicado: (2023)

‘Hearts and minds’: association, causation and implication of cognitive impairment in heart failure
por: Cannon, Jane A, et al.
Publicado: (2015)

Drug therapy for heart failure with reduced ejection fraction: what is the ‘right’ dose?
por: Kondo, Toru, et al.
Publicado: (2022)

Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019)

Estimating the Lifetime Benefits of Treatments for Heart Failure
por: Ferreira, João Pedro, et al.
Publicado: (2020)

SOLOIST‐WHF and updated meta‐analysis: sodium–glucose co‐transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure
por: Docherty, Kieran F., et al.
Publicado: (2020)

Which patients with heart failure should receive specialist palliative care?
por: Campbell, Ross T., et al.
Publicado: (2018)

Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF
por: McEwan, Phil, et al.
Publicado: (2020)

Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction
por: Serenelli, Matteo, et al.
Publicado: (2020)

Adverse Outcomes Associated With Interleukin-6 in Patients Recently Hospitalized for Heart Failure With Preserved Ejection Fraction
por: Mooney, Leanne, et al.
Publicado: (2023)

Talking about end-of-life care in a timely manner
por: Smeenk, Frank W.J.M., et al.
Publicado: (2017)

Treatment of Type 2 Diabetes and Outcomes in Patients With Heart Failure: A Nested Case–Control Study From the U.K. General Practice Research Database
por: MacDonald, Michael R., et al.
Publicado: (2010)

Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction
por: Rørth, Rasmus, et al.
Publicado: (2019)

WE’RE NEVER TALKING ABOUT IT: POLICY AND PRACTICE ABOUT END OF LIFE IN ASSISTED LIVING
por: Bender, Alexis A, et al.
Publicado: (2019)

Sex differences in congestive markers in patients hospitalized for acute heart failure
por: Espersen, Caroline, et al.
Publicado: (2021)

The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure
por: Campbell, Ross T., et al.
Publicado: (2020)

Initiation of domiciliary care and nursing home admission following first hospitalization of heart failure patients: a nationwide cohort study
por: Rørth, Rasmus, et al.
Publicado: (2018)

Post hoc analyses of SHIFT and PARADIGM‐HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: “Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial” by Bocchi et al.
por: Ramires, Felix J.A., et al.
Publicado: (2018)

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2021)

Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program
por: Preiss, David, et al.
Publicado: (2009)

Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study
por: Felker, G. Michael, et al.
Publicado: (2020)

Insights into foundational therapies for heart failure with reduced ejection fraction
por: McMurray, John J. V., et al.
Publicado: (2022)

Winter Peaks in Heart Failure: An Inevitable or Preventable Consequence of Seasonal Vulnerability?
por: Stewart, Simon, et al.
Publicado: (2019)

Comparison of Troponin Elevation, Prior Myocardial Infarction, and Chest Pain in Acute Ischemic Heart Failure
por: Freitas, Cassandra, et al.
Publicado: (2020)

Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis
por: Burnett, Heather, et al.
Publicado: (2017)

The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan
por: Jhund, Pardeep S, et al.
Publicado: (2016)

A palliative approach for heart failure end-of-life care
por: Maciver, Jane, et al.
Publicado: (2018)

Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)
por: Lee, Matthew M.Y., et al.
Publicado: (2020)

Talking about the end of life: communication patterns in amyotrophic lateral sclerosis – a scoping review
por: Erdmann, Anke, et al.
Publicado: (2022)

Communication about Prognosis and End-of-Life in Heart Failure Care and Experiences Using a Heart Failure Question Prompt List
por: Hjelmfors, Lisa, et al.
Publicado: (2022)

Let us talk about death: gender effects in cancer patients’ preferences for end-of-life discussions
por: Seifart, C., et al.
Publicado: (2020)

What We Talk About When We Talk About Evolution
por: Torday, John S.
Publicado: (2015)

Advance Care Planning and End-of-Life Education in Heart Failure: Insights From the NCDR PINNACLE Registry
por: Cavanagh, Casey E., et al.
Publicado: (2023)

Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial
por: Kosiborod, Mikhail N., et al.
Publicado: (2020)

The Meaning of Diagnosis for Different Designations in Talking About Autism
por: Tepest, Ralf
Publicado: (2020)

Talks about Food: V. The Staff of Life
Publicado: (1892)

Cannot write session to /tmp/vufind_sessions/sess_8rqrncgjciti82549ufdm5tcfh